Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab

Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab
复制标题

诱导化疗后单倍相合外周血干细胞移植和利妥昔单抗治疗移植后淋巴增殖性疾病

DOI:
--
复制
发表时间:
2001
影响因子:
4.8
通讯作者:
J. Wingard
J. Wingard
中科院分区:
医学3区
文献类型:
--
作者:
S. Skoda;V. Douglas;Paulette Mehta;John Graham;J. Wingard

文献摘要

参考文献

被引文献

相似文献

干细胞移植后单克隆淋巴增殖性疾病的治疗很困难,之前单独使用化疗或放疗来根除肿瘤的尝试尚未成功。我们报道了一名因严重联合免疫缺陷病而接受 T 细胞耗尽、母体单倍相合骨髓移植的儿童的 EBV 阴性 B 细胞非霍奇金淋巴瘤的早期成功根除。我们的治疗策略包括将传统诱导化疗与使用父亲供体作为外周血干细胞来源的再移植相结合,然后使用抗 CD 20 单克隆抗体(利妥昔单抗)进行治疗。该策略利用了移植物中成熟 T 细胞的潜在移植物抗肿瘤活性,同时提供干细胞来源以赋予长期免疫功能。在移植后早期使用利妥昔单抗可以提供额外的抗肿瘤活性,而不影响新的干细胞区室。骨髓移植 (2001) 27, 329–332。
Management of monoclonal lymphoproliferative disease following stem cell transplantation is difficult and previous attempts to eradicate tumor using chemotherapy or radiation therapy alone have not been successful. We report successful early eradication of an EBV negative, B cell non-Hodgkin's lymphoma in a child who received a T cell-depleted, maternal haploidentical bone marrow transplant for severe combined immunodeficiency disease. Our treatment strategy involved combining conventional induction chemotherapy with re-transplantation using the paternal donor as a source of peripheral blood stem cells, followed by treatment with anti-CD 20 monoclonal antibody (Rituximab). This strategy exploits the potential graft-versus-tumor activity of the mature T cells in the graft, while providing a source of stem cells to confer long-term immune function. The administration of Rituximab in the early post-transplant course may provide additional anti-tumor activity without affecting the new stem cell compartment. Bone Marrow Transplantation (2001) 27, 329–332.
DOI: 10.1056/nejm199404283301703
发表时间: 1994-04-28
影响因子: 158.5
作者:
PAPADOPOULOS, EB;LADANYI, M;OREILLY, RJ
通讯作者: OREILLY, RJ
通过逆流淘洗去除供体骨髓中 EBV 感染的细胞。
DOI: --
发表时间: 1998
影响因子: 2.6
作者:
Gross,TG;Hinrichs,SH;Davis,JR;Mitchell,D;Bishop,MR;Wagner,JE
通讯作者: Wagner,JE